

## REFERENCES

1. Dorrington, R.E., et al., The demographic impact of HIV/AIDS in South Africa. National and provincial indicators for 2006. 2006, Cape Town: Centre for Actuarial Research, South African Medical Research Council, Actuarial Society of South Africa.: Cape Town.  
<http://www.mrc.ac.za/bod/DemographicImpactHIVIndicators.pdf>.
2. Raphael, M., et al., Lymphomas associated with HIV infection, in *WHO Classification of tumours of haematopoietic and lymphoid tissues*, S.H. Swerdlow, et al., Editors. 2008, IARC Press: Lyon, France. 340-349.
3. Diamond, C., et al., Presentation and outcomes of systemic non-Hodgkin's lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS. *Leuk Lymphoma*, 2006. 47(9): 1822-9.
4. Engels, E.A., et al., Trends in cancer risk among people with AIDS in the United States 1980-2002. *Aids*, 2006. 20(12): 1645-54.
5. Delecluse, H.J., et al., Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. *Blood*, 1997. 89(4): 1413-20.
6. Scheper, M.A., et al., Oral plasmablastic lymphoma in an HIV-negative patient: a case report and review of the literature. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*, 2005. 100(2): 198-206.
7. Castillo, J., L. Pantanowitz, and B.J. Dezube, HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. *Am J Hematol*, 2008. 83(10): 804-9.
8. Riedel, D.J., et al., Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection. *Lancet Infect Dis*, 2008. 8(4): 261-7.
9. Swerdlow, S.H., E. Campo, and N. Harris, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. WHO. 2008, Lyon, France: IARC Press.
10. Boy, S.C., et al., Plasmablastic lymphomas with light chain restriction - plasmablastic extramedullary plasmacytomas? *J Oral Pathol Med*, 2010. 39(5): 435-9.
11. Taddesse-Heath, L., et al., Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. *Mod Pathol*, 2010. 23(7): 991-9.

12. Bose, P., et al., AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib. *Eur J Haematol*, 2009. 82(6): 490-2.
13. Valera, A., et al., IG/MYC Rearrangements are the Main Cytogenetic Alteration in Plasmablastic Lymphomas. *Am J Surg Pathol*, 2010. 34(11): 1686-94.
14. Ferrazzo, K.L., et al., EBV detection in HIV-related oral plasmablastic lymphoma. *Oral Dis*, 2007. 13(6): 564-9.
15. Carbone, A., et al., Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. *Blood*, 2001. 97(3): 744-51.
16. Cioc, A.M., et al., Oral plasmablastic lymphomas in AIDS patients are associated with human herpesvirus 8. *Am J Surg Pathol*, 2004. 28(1): 41-6.
17. Dong, H.Y., et al., Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm. *Am J Surg Pathol*, 2005. 29(12): 1633-41.
18. Goedhals, J., C.A. Beukes, and D. Hardie, HHV8 in Plasmablastic Lymphoma. *Am J Surg Pathol*, 2008. 32(1): 172.
19. Martin, C.A., M. Narbaitz, and S. Sapia, Plasmablastic lymphomas: immunohistochemical characteristics and in situ hybridization analysis for EBV and HHV-8 viruses. *Mod Pathol*, 2003. 16: 246.
20. Toure, G., et al., Plasmablastic lymphoma: a case report. *Quintessence Int*, 2007. 38(2): 161-3.
21. Said, J., Diffuse aggressive B-cell lymphomas. *Adv Anat Pathol*, 2009. 16(4): 216-235.
22. Stein, H., N.L. Harris, and E. Campo, Plasmablastic lymphoma, in *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*, S.H. Swerdlow, E. Campo, and N.L. Harris, Editors. 2008, IARC: Lyon, France. 256-257.
23. Jaffe, E.S., et al., Pathology and Genetics of Tumours of Haematopoietic and lymphoid Tissues. World Health Organization Classification of Tumours, ed. P. Kleihues and L.H. Sobin. 2001, Lyon, France: IARC Press. 352.
24. Chuah, K.L., et al., Plasmablastic lymphoma affecting the lung and bone marrow with CD10 expression and t(8;14)(q24;q32) translocation. *Int J Surg Pathol*, 2009. 17(2): 163-6.
25. Bogusz, A.M., et al., Plasmablastic lymphomas with MYC/IgH rearrangement. Report of three cases and review of the literature. *Am J Clin Pathol*, 2010. 132: 597-605.

26. Dawson, M.A., et al., AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH/MYC translocation--treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A. *Haematologica*, 2007. 92(1): e11-2.
27. Seegmiller, A.C., et al., Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas. *Mod Pathol*, 2010. 23(7): 909-20.
28. Balague, O., A. Martinez, and L. Colomo, Plasmablastic lymphomas (PBL) are genetically characterized by frequent MYC translocations [abstract]. *Mod Pathol*, 2009. 22: 255A.
29. Jaffe, E.S., et al., Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. *Blood*, 2008. 112(12): 4384-99.
30. Hasserjian, R.P., et al., Commentary on the WHO classification of tumors of lymphoid tissues (2008): "Gray zone" lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma. *J Hematop*, 2009. 2(2): 89-95.
31. Hassan, A., et al., Plasmablastic lymphoma of head and neck: report of two new cases and correlation with c-myc and IgVH gene mutation status. *Head Neck Pathol*, 2007. 1(2): 150-5.
32. Lin, Y., et al., Plasmablastic lymphoma of the lung: report of a unique case and review of the literature. *Arch Pathol Lab Med*, 2001. 125(2): 282-5.
33. Brown, R.S., et al., Plasmablastic lymphoma: a new subcategory of human immunodeficiency virus-related non-Hodgkin's lymphoma. *Clin Oncol (R Coll Radiol)*, 1998. 10(5): 327-9.
34. Porter, S.R., et al., Oral plasmablastic lymphoma in previously undiagnosed HIV disease. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*, 1999. 87(6): 730-4.
35. Borrero, J.J., et al., Plasmablastic lymphoma of the oral cavity and jaws. *Aids*, 2002. 16(14): 1979-80.
36. Flaitz, C.M., et al., Plasmablastic lymphoma: an HIV-associated entity with primary oral manifestations. *Oral Oncol*, 2002. 38(1): 96-102.
37. Gaidano, G., et al., Molecular histogenesis of plasmablastic lymphoma of the oral cavity. *Br J Haematol*, 2002. 119(3): 622-8.
38. Lester, R., et al., Improved outcome of human immunodeficiency virus-associated plasmablastic lymphoma of the oral cavity in the era of highly active antiretroviral therapy: a report of two cases. *Leuk Lymphoma*, 2004. 45(9): 1881-5.

39. Cattaneo, C., et al., Oral cavity lymphomas in immunocompetent and human immunodeficiency virus infected patients. *Leuk Lymphoma*, 2005. 46(1): 77-81.
40. Radhakrishnan, R., et al., Plasmablastic lymphoma of the oral cavity in an HIV-positive child. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*, 2005. 100(6): 725-31.
41. Folk, G.S., et al., Plasmablastic lymphoma: a clinicopathologic correlation. *Ann Diagn Pathol*, 2006. 10(1): 8-12.
42. Lee, O.J., K.W. Kim, and G.K. Lee, Epstein-Barr virus and human immunodeficiency virus-negative oral plasmablastic lymphoma. *J Oral Pathol Med*, 2006. 35(6): 382-4.
43. Tavora, F., et al., Extra-oral plasmablastic lymphoma: report of a case and review of literature. *Hum Pathol*, 2006. 37(9): 1233-6.
44. Armstrong, R., J. Bradrick, and Y.C. Liu, Spontaneous regression of an HIV-associated plasmablastic lymphoma in the oral cavity: a case report. *J Oral Maxillofac Surg*, 2007. 65(7): 1361-4.
45. Desai, R.S., et al., Plasmablastic lymphoma presenting as a gingival growth in a previously undiagnosed HIV-positive patient: a case report. *J Oral Maxillofac Surg*, 2007. 65(7): 1358-61.
46. Ortega, K.L., et al., Images in HIV/AIDS. Oral plasmablastic lymphoma. *AIDS Read*, 2007. 17(9): 446-7.
47. Panos, G., et al., Prolonged survival of an HIV-infected patient with plasmablastic lymphoma of the oral cavity. *Am J Hematol*, 2007. 82(8): 761-5.
48. Carbone, A., A. Gloghini, and G. Gaidano, Is plasmablastic lymphoma of the oral cavity an HHV-8-associated disease? *Am J Surg Pathol*, 2004. 28(11): 1538-40; author reply 1540.
49. Pruneri, G., et al., Plasmablastic lymphoma of the stomach. A case report. *Haematologica*, 1998. 83(1): 87-9.
50. Robak, T., et al., Plasmablastic lymphoma in a patient with chronic lymphocytic leukemia heavily pretreated with cladribine (2-CdA): an unusual variant of Richter's syndrome. *Eur J Haematol*, 2001. 67(5-6): 322-7.
51. Nasta, S.D., et al., Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy. *Leuk Lymphoma*, 2002. 43(2): 423-6.
52. Chetty, R., et al., Plasmablastic lymphoma in HIV+ patients: an expanding spectrum. *Histopathology*, 2003. 42(6): 605-9.

53. Nguyen, D.D., et al., Plasmablastic lymphoma presenting in a human immunodeficiency virus-negative patient: a case report. *Ann Hematol*, 2003. 82(8): 521-5.
54. Nicol, I., et al., Post-transplant plasmablastic lymphoma of the skin. *Br J Dermatol*, 2003. 149(4): 889-91.
55. Ojanguren, J., et al., Epstein-Barr virus-related plasmablastic lymphomas arising from long-standing sacrococcygeal cysts in immunosuppressed patients. *Aids*, 2003. 17(10): 1582-4.
56. Colomo, L., et al., Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. *Am J Surg Pathol*, 2004. 28(6): 736-47.
57. Hausermann, P., et al., Cutaneous plasmablastic lymphoma in an HIV-positive male: an unrecognized cutaneous manifestation. *Dermatology*, 2004. 208(3): 287-90.
58. Lin, F., et al., Plasmablastic lymphoma of the cervical lymph nodes in a human immunodeficiency virus-negative patient: a case report and review of the literature. *Arch Pathol Lab Med*, 2004. 128(5): 581-4.
59. Schichman, S.A., et al., HIV and plasmablastic lymphoma manifesting in sinus, testicles, and bones: a further expansion of the disease spectrum. *Am J Hematol*, 2004. 77(3): 291-5.
60. Sharma, R., et al., Disseminated plasmablastic lymphoma. *J Am Coll Surg*, 2004. 199(4): 654-5.
61. Teruya-Feldstein, J., et al., CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients. *Ann Oncol*, 2004. 15(11): 1673-9.
62. Dales, J.P., et al., [Plasmablastic lymphoma in a patient with HIV infection: an unusual case located in the skin]. *Ann Pathol*, 2005. 25(1): 45-9.
63. Jordan, L.B., A.M. Lessells, and J.R. Goodlad, Plasmablastic lymphoma arising at a cutaneous site. *Histopathology*, 2005. 46(1): 113-5.
64. Verma, S., et al., Epstein-Barr virus- and human herpesvirus 8-associated primary cutaneous plasmablastic lymphoma in the setting of renal transplantation. *J Cutan Pathol*, 2005. 32(1): 35-9.
65. Goedhals, J., C.A. Beukes, and S. Cooper, The ultrastructural features of plasmablastic lymphoma. *Ultrastruct Pathol*, 2006. 30(6): 427-33.
66. Kravetz, J.D., et al., Plasmablastic lymphoma presenting as an arm mass in an individual negative for human immunodeficiency virus: a case report. *Clin Lymphoma Myeloma*, 2006. 6(6): 493-5.

67. Liu, W., et al., KSHV/HHV8-associated primary cutaneous plasmablastic lymphoma in a patient with Castleman's disease and Kaposi's sarcoma. *J Cutan Pathol*, 2006. 33 Suppl 2: 46-51.
68. Chen, Y.B., et al., AIDS-associated plasmablastic lymphoma presenting at the insertion site of a peritoneal dialysis catheter. *J Clin Oncol*, 2007. 25(21): 3176-8.
69. Masgala, A., et al., Plasmablastic lymphoma of visceral cranium, cervix and thorax in an HIV-negative woman. *Ann Hematol*, 2007. 86(8): 615-8.
70. Rajagopal, A.S., et al., Plasmablastic lymphoma: a case of rectal disease with spinal cord compression. *Leuk Lymphoma*, 2006. 47(12): 2670-3.
71. Redmond, M., et al., Plasmablastic lymphoma presenting as a paravertebral mass in a patient with Crohn's disease after immunosuppressive therapy. *J Clin Pathol*, 2007. 60(1): 80-1.
72. Kane, S., et al., Minimum diagnostic criteria for plasmablastic lymphoma of oral/sinonasal region encountered in a tertiary cancer hospital of a developing country. *J Oral Pathol Med*, 2009. 38(1): 138-44.
73. Sarode, S.C., et al., Plasmablastic lymphoma of the oral cavity in an HIV-positive patient: a case report and review of literature. *Int J Oral Maxillofac Surg*, 2009.
74. Tzankov, A., et al., Incidental oral plasmablastic lymphoma with aberrant expression of CD4 in an elderly HIV-negative patient: how a gingival polyp can cause confusion. *Histopathology*, 2005. 46(3): 348-50.
75. Anup, N., et al., Splenic tumor presenting as pyrexia of unknown origin. *J Assoc Physicians India*, 2007. 55: 805-7.
76. Assanasen, T., et al., Extranodal malignant lymphoma of the upper aerodigestive tract: prevalence of Epstein-Barr virus (EBV) infection in King Chulalongkorn Memorial Hospital. *J Med Assoc Thai*, 2005. 88 Suppl 4: S266-73.
77. Deloose, S.T., et al., High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma. *Leukemia*, 2005. 19(5): 851-5.
78. Barkhuysen, R., et al., Plasmablastic lymphoma mimicking orbital cellulitis. *Oral Maxillofac Surg*, 2008. 12(3): 125-8.
79. Valenzuela, A.A., N.J. Walker, and T.J. Sullivan, Plasmablastic lymphoma in the orbit: case report. *Orbit*, 2008. 27(3): 227-9.
80. Bittencourt, A.L., et al., Burkitt's lymphoma of the scapula. *Pediatr Pathol Mol Med*, 2003. 22(4): 271-6.



81. Mani, D., D.G. Guinee, Jr., and D.M. Aboulaflia, AIDS-associated plasmablastic lymphoma presenting as a poorly differentiated esophageal tumor: a diagnostic dilemma. *World J Gastroenterol*, 2008. 14(27): 4395-9.
82. Wang, J., O.J. Hernandez, and F. Sen, Plasmablastic lymphoma involving breast: a case diagnosed by fine-needle aspiration and core needle biopsy. *Diagn Cytopathol*, 2008. 36(4): 257-61.
83. Miller, D.V., et al., Primary cardiac plasmablastic (diffuse large B-cell) lymphoma mimicking left ventricular aneurysm with mural thrombus. *Cardiovasc Pathol*, 2007. 16(2): 111-4.
84. Surti, K.M. and P.W. Ralls, Sonographic appearance of plasmablastic lymphoma of the testes. *J Ultrasound Med*, 2008. 27(6): 965-7.
85. Shuangshoti, S., et al., Primary central nervous system plasmablastic lymphoma in AIDS. *Neuropathol Appl Neurobiol*, 2007.
86. Ustun, C., et al., Plasmablastic lymphoma: CNS involvement, coexistence of other malignancies, possible viral etiology, and dismal outcome. *Ann Hematol*, 2009. 88(4): 351-8.
87. Carbone, A., et al., AIDS-related plasmablastic lymphomas of the oral cavity and jaws: a diagnostic dilemma. *Ann Otol Rhinol Laryngol*, 1999. 108(1): 95-9.
88. Antinori, A., et al., Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. *Aids*, 2001. 15(12): 1483-91.
89. Navarro, J.T., et al., Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. *Br J Haematol*, 2001. 112(4): 909-15.
90. Teruya-Feldstein, J., Diffuse large B-cell lymphomas with plasmablastic differentiation. *Curr Oncol Rep*, 2005. 7(5): 357-63.
91. Gujral, S., T.M. Shet, and S.V. Kane, Morphological spectrum of AIDS-related plasmablastic lymphomas. *Indian J Pathol Microbiol*, 2008. 51(1): 121-4.
92. Vega, F., et al., Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. *Mod Pathol*, 2005. 18(6): 806-15.
93. Carbone, A. and A. Gloghini, Plasmablastic lymphoma: one or more entities? *Am J Hematol*, 2008. 83(10): 763-4.

94. Arbiser, J.L., et al., Presence of p16 hypermethylation and Epstein-Barr virus infection in transplant-associated hematolymphoid neoplasm of the skin. *J Am Acad Dermatol*, 2006. 55(5): 794-8.
95. Stein, H., et al., Diffuse large B-cell lymphoma, not otherwise specified, in *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*, S.H. Swerdlow, et al., Editors. 2008, IARC: Lyon, France. 233-237.
96. Chan, J.K., K. Aozasa, and P. Gaulard, Diffuse Large B-cell Lymphoma associated with chronic inflammation, in *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*, S.H. Swerdlow, et al., Editors. 2008, IARC: Lyon, France.
97. Delsol, G., E. Campo, and R.D. Gascoyne, ALK-positive large B-cell lymphoma, in *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*, S.H. Swerdlow, et al., Editors. 2008, IARC: Lyon, France. 254-255.
98. Isaacson, P.G., E. Campo, and N.L. Harris, Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease, in *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*, S.H. Swerdlow, et al., Editors. 2008, IARC: Lyon, France. 258-259.
99. Said, J. and E. Cesarman, Primary effusion lymphoma, in *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*, S.H. Swerdlow, et al., Editors. 2008, IARC: Lyon, France. 260-261.
100. Kyle, R.A. and S.V. Rajkumar, Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. *Leukemia*, 2009. 23(1): 3-9.
101. Yotsumoto, M., et al., CD20-negative CD138-positive leukemic large cell lymphoma with plasmablastic differentiation with an IgH/MYC translocation in an HIV-positive patient. *Intern Med*, 2009. 48(7): 559-62.
102. Simonitsch-Klupp, I., et al., Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome. *Leukemia*, 2004. 18(1): 146-55.
103. Hummel, M., et al., A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. *N Engl J Med*, 2006. 354(23): 2419-30.
104. Fiorino, A.S. and B. Atac, Paraproteinemia, plasmacytoma, myeloma and HIV infection. *Leukemia*, 1997. 11(12): 2150-6.
105. Kumar, S., et al., Plasma cell myeloma in patients who are HIV-positive. *Am J Clin Pathol*, 1994. 102(5): 633-9.
106. Chang, S.T., et al., Plasmablastic cytomorphic features in plasma cell neoplasms in immunocompetent patients are significantly associated with EBV. *Am J Clin Pathol*, 2007. 128(2): 339-44.



107. Salarieh, A., et al., Plasma cell tumors in HIV-positive patients: report of a case and review of the literature. *Leuk Lymphoma*, 2005. 46(7): 1067-74.
108. Kyle, R.A. and S.V. Rajkumar, Multiple myeloma. *Blood*, 2008. 111(6): 2962-72.
109. McKenna, R.W., et al., Plasma cell neoplasias, in *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*, S.H. Swerdlow, et al., Editors. 2008, IARC: Lyon, France. 200-213.
110. Qi, C.F., et al., Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells. *Cancer Res*, 2007. 67(6): 2439-47.
111. Anon, Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. *Br J Haematol*, 2003. 121(5): 749-57.
112. Delauche-Cavallier, M.C., et al., Solitary plasmacytoma of the spine. Long-term clinical course. *Cancer*, 1988. 61(8): 1707-14.
113. Holland, J., et al., Plasmacytoma. Treatment results and conversion to myeloma. *Cancer*, 1992. 69(6): 1513-7.
114. Alexiou, C., et al., Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. *Cancer*, 1999. 85(11): 2305-14.
115. Goedert, J.J., et al., Spectrum of AIDS-associated malignant disorders. *Lancet*, 1998. 351(9119): 1833-9.
116. Grulich, A.E., et al., Risk of cancer in people with AIDS. *Aids*, 1999. 13(7): 839-43.
117. Grulich, A.E., et al., Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. *Aids*, 2002. 16(8): 1155-61.
118. Frisch, M., et al., Association of cancer with AIDS-related immunosuppression in adults. *JAMA*, 2001. 285(13): 1736-45.
119. Nador, R.G., et al., Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. *Blood*, 1996. 88(2): 645-56.
120. Dupin, N., et al., HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. *Blood*, 2000. 95(4): 1406-12.
121. Laurence, J. and S.M. Astrin, Human immunodeficiency virus induction of malignant transformation in human B lymphocytes. *Proc Natl Acad Sci U S A*, 1991. 88(17): 7635-9.
122. Knowles, D.M., Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma. *Hematol Oncol Clin North Am*, 2003. 17(3): 785-820.

123. Grogg, K.L., R.F. Miller, and A. Dogan, HIV infection and lymphoma. *J Clin Pathol*, 2007. 60(12): 1365-72.
124. Castella, A., et al., The bone marrow in AIDS. A histologic, hematologic, and microbiologic study. *Am J Clin Pathol*, 1985. 84(4): 425-32.
125. Konrad, R.J., et al., Brief report: myeloma-associated paraprotein directed against the HIV-1 p24 antigen in an HIV-1-seropositive patient. *N Engl J Med*, 1993. 328(25): 1817-9.
126. Jin, D.K., et al., Hyperviscosity syndrome secondary to a myeloma-associated IgG(1)kappa paraprotein strongly reactive against the HIV-1 p24 gag antigen. *Am J Hematol*, 2000. 64(3): 210-3.
127. Shacter, E. and G. Arzadon, Elevation of IL-6 in plasma cell tumorigenesis. *AIDS Res Hum Retroviruses*, 1992. 8(5): 754-6.
128. Gold, J.E., et al., Malignant plasma cell tumors in human immunodeficiency virus-infected patients. *Cancer*, 1990. 66(2): 363-8.
129. Nosari, A.M., et al., Multiple myeloma associated to HIV infection: report of two patients. *Eur J Haematol*, 1996. 56(1-2): 98-9.
130. Ramadan, A., et al., Testicular plasmacytoma in a patient with the acquired immunodeficiency syndrome. *Tumori*, 2000. 86(6): 480-2.
131. Kyle, R.A., et al., Review of 1027 patients with newly diagnosed multiple myeloma. *Mayo Clin Proc*, 2003. 78(1): 21-33.
132. Purtilo, D.T., et al., Epstein-Barr virus-associated lymphoproliferative disorders. *Lab Invest*, 1992. 67(1): 5-23.
133. Okano, M. and T.G. Gross, A review of Epstein-Barr virus infection in patients with immunodeficiency disorders. *Am J Med Sci*, 2000. 319(6): 392-6.
134. Carbone, A., et al., HIV-associated lymphomas and gamma-herpesviruses. *Blood*, 2009. 113(6): 1213-24.
135. Raphael, M., Lymphomas associated with infection by the human immune deficiency virus (HIV), in *World Health Organization classification of tumours, pathology and genetics of haematopoietic and lymphoid tissues*, E.S. Jaffe, et al., Editors. 2001, IARC Press: Lyon, France. 260-3.
136. Kim, J.E., et al., Human immunodeficiency virus-negative plasmablastic lymphoma in Korea. *Leuk Lymphoma*, 2009. 50(4): 582-7.
137. Cesarman, E. and E.A. Mesri, Kaposi sarcoma-associated herpesvirus and other viruses in human lymphomagenesis. *Curr Top Microbiol Immunol*, 2007. 312: 263-87.
138. Oksenhendler, E., et al., High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. *Blood*, 2002. 99(7): 2331-6.

139. Areste, C. and D.J. Blackbourn, Modulation of the immune system by Kaposi's sarcoma-associated herpesvirus. *Trends Microbiol*, 2009. 17(3): 119-29.
140. Carbone, A., et al., AIDS-related extranodal non-Hodgkin's lymphomas with plasma cell differentiation. *Blood*, 1997. 90(3): 1337-8.
141. Webster-Cyriaque, J., et al., Epstein-Barr virus and human herpesvirus 8 prevalence in human immunodeficiency virus-associated oral mucosal lesions. *J Infect Dis*, 1997. 175(6): 1324-32.
142. Brown, R.S., et al., Absence of immunohistochemical evidence for human herpesvirus 8 (HHV8) in oral cavity plasmablastic lymphoma in an HIV-positive man. *Clin Oncol (R Coll Radiol)*, 2000. 12(3): 194.
143. Boveri, T., Zur Frage der Entstehung maligner tumoren, in *Gustav Fisher verlag*. 1914.
144. Mitelman, F., B. Johansson, and F. Mertens, The impact of translocations and gene fusions on cancer causation. *Nat Rev Cancer*, 2007. 7(4): 233-45.
145. Vogelstein, B. and K.W. Kinzler, Cancer genes and the pathways they control. *Nat Med*, 2004. 10(8): 789-99.
146. Friedberg, E.C., DNA damage and repair. *Nature*, 2003. 421(6921): 436-40.
147. Kuppers, R., Mechanisms of B-cell lymphoma pathogenesis. *Nat Rev Cancer*, 2005. 5(4): 251-62.
148. Nussenzweig, A. and M.C. Nussenzweig, Origin of chromosomal translocations in lymphoid cancer. *Cell*, 2010. 141(1): 27-38.
149. Sagaert, X., B. Sprangers, and C. De Wolf-Peeters, The dynamics of the B follicle: understanding the normal counterpart of B-cell-derived malignancies. *Leukemia*, 2007. 21(7): 1378-86.
150. Duchosal, M.A., B-cell development and differentiation. *Semin Hematol*, 1997. 34(1 Suppl 1): 2-12.
151. Burrows, P.D. and M.D. Cooper, B cell development and differentiation. *Curr Opin Immunol*, 1997. 9(2): 239-44.
152. Shapiro-Shelef, M. and K. Calame, Regulation of plasma-cell development. *Nat Rev Immunol*, 2005. 5(3): 230-42.
153. Chen, H.T., et al., Response to RAG-mediated VDJ cleavage by NBS1 and gamma-H2AX. *Science*, 2000. 290(5498): 1962-5.
154. de Villartay, J.P., V(D)J recombination deficiencies. *Adv Exp Med Biol*, 2009. 650: 46-58.
155. Wilson, P.C., et al., Somatic hypermutation introduces insertions and deletions into immunoglobulin V genes. *J Exp Med*, 1998. 187(1): 59-70.

156. Peled, J.U., et al., The biochemistry of somatic hypermutation. *Annu Rev Immunol*, 2008. 26: 481-511.
157. Schmidlin, H., S.A. Diehl, and B. Blom, New insights into the regulation of human B-cell differentiation. *Trends Immunol*, 2009. 30(6): 277-85.
158. Fukuda, T., et al., Disruption of the Bcl6 gene results in an impaired germinal center formation. *J Exp Med*, 1997. 186(3): 439-48.
159. Fairfax, K.A., et al., Plasma cell development: from B-cell subsets to long-term survival niches. *Semin Immunol*, 2008. 20(1): 49-58.
160. Shaffer, A.L., et al., BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. *Immunity*, 2000. 13(2): 199-212.
161. Ye, B.H., et al., The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. *Nat Genet*, 1997. 16(2): 161-70.
162. Chaudhuri, J. and F.W. Alt, Class-switch recombination: interplay of transcription, DNA deamination and DNA repair. *Nat Rev Immunol*, 2004. 4(7): 541-52.
163. Klein, U. and R. Dalla-Favera, Germinal centres: role in B-cell physiology and malignancy. *Nat Rev Immunol*, 2008. 8(1): 22-33.
164. Kuppers, R., et al., Cellular origin of human B-cell lymphomas. *N Engl J Med*, 1999. 341(20): 1520-9.
165. Stevenson, F., et al., Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes. *Immunol Rev*, 1998. 162: 247-59.
166. Willis, T.G. and M.J. Dyer, The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. *Blood*, 2000. 96(3): 808-22.
167. Bernicot, I., et al., Characterization of IGH rearrangements in non-Hodgkin's B-cell lymphomas by fluorescence in situ hybridization. *Anticancer Res*, 2005. 25(5): 3179-82.
168. Arakawa, H., J. Hauschild, and J.M. Buerstedde, Requirement of the activation-induced deaminase (AID) gene for immunoglobulin gene conversion. *Science*, 2002. 295(5558): 1301-6.
169. Franco, S., F.W. Alt, and J.P. Manis, Pathways that suppress programmed DNA breaks from progressing to chromosomal breaks and translocations. *DNA Repair (Amst)*, 2006. 5(9-10): 1030-41.
170. Ramiro, A.R., et al., AID is required for c-myc/IgH chromosome translocations in vivo. *Cell*, 2004. 118(4): 431-8.
171. Robbiani, D.F., et al., AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. *Cell*, 2008. 135(6): 1028-38.

172. Chesi, M., et al., AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. *Cancer Cell*, 2008. 13(2): 167-80.
173. Richardson, C. and M. Jasin, Frequent chromosomal translocations induced by DNA double-strand breaks. *Nature*, 2000. 405(6787): 697-700.
174. Branco, M.R. and A. Pombo, Intermingling of chromosome territories in interphase suggests role in translocations and transcription-dependent associations. *PLoS Biol*, 2006. 4(5): e138.
175. Parada, L.A., P.G. McQueen, and T. Misteli, Tissue-specific spatial organization of genomes. *Genome Biol*, 2004. 5(7): R44.
176. Roix, J.J., et al., Spatial proximity of translocation-prone gene loci in human lymphomas. *Nat Genet*, 2003. 34(3): 287-91.
177. Osborne, C.S., et al., Myc dynamically and preferentially relocates to a transcription factory occupied by Igh. *PLoS Biol*, 2007. 5(8): e192.
178. Robbiani, D.F., et al., AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations. *Mol Cell*, 2009. 36(4): 631-41.
179. Ramiro, A.R., et al., Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. *Nature*, 2006. 440(7080): 105-9.
180. Pasqualucci, L., et al., Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. *Nature*, 2001. 412(6844): 341-6.
181. Pasqualucci, L., et al., BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. *Proc Natl Acad Sci U S A*, 1998. 95(20): 11816-21.
182. Liu, M., et al., Two levels of protection for the B cell genome during somatic hypermutation. *Nature*, 2008. 451(7180): 841-5.
183. Mullighan, C.G., et al., Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. *Nature*, 2007. 446(7137): 758-64.
184. Callen, E., et al., ATM prevents the persistence and propagation of chromosome breaks in lymphocytes. *Cell*, 2007. 130(1): 63-75.
185. Wang, J.H., et al., Mechanisms promoting translocations in editing and switching peripheral B cells. *Nature*, 2009. 460(7252): 231-6.
186. Wang, J.H., et al., Oncogenic transformation in the absence of Xrcc4 targets peripheral B cells that have undergone editing and switching. *J Exp Med*, 2008. 205(13): 3079-90.
187. Gronbaek, K., et al., Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. *Blood*, 1998. 92(9): 3018-24.

188. Sheiness, D. and J.M. Bishop, DNA and RNA from uninfected vertebrate cells contain nucleotide sequences related to the putative transforming gene of avian myelocytomatosis virus. *J Virol*, 1979. 31: 514-521.
189. Henriksson, M. and B. Lubcher, Proteins of the Myc network: Essential regulators of cell growth and differentiation. *Adv Cancer Res*, 1996. 68: 109-182.
190. Dalla-Favera, R., et al., Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. *Proc Natl Acad Sci U S A*, 1982. 79(24): 7824-7.
191. Hann, S.R., et al., The alternatively initiated c-Myc proteins differentially regulate transcription through a noncanonical DNA-binding site. *Genes Dev*, 1994. 8(20): 2441-52.
192. Albiñ, A., J.I. Johnsen, and M.A. Henriksson, MYC in oncogenesis and as a target for cancer therapies. *Adv Cancer Res*, 2010. 107: 163-224.
193. Conzen, S.D., et al., Induction of cell cycle progression and acceleration of apoptosis are two separable functions of c-Myc: transrepression correlates with acceleration of apoptosis. *Mol Cell Biol*, 2000. 20(16): 6008-18.
194. Meyer, N. and L.Z. Penn, Reflecting on 25 years with MYC. *Nat Rev Cancer*, 2008. 8(12): 976-90.
195. Baena, E., et al., c-Myc is essential for hematopoietic stem cell differentiation and regulates Lin(-)Sca-1(+)c-Kit(-) cell generation through p21. *Exp Hematol*, 2007. 35(9): 1333-43.
196. Cartwright, P., et al., LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism. *Development*, 2005. 132(5): 885-96.
197. Hann, S.R., Role of post-translational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function. *Semin Cancer Biol*, 2006. 16(4): 288-302.
198. Harrington, E.A., et al., c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. *Embo J*, 1994. 13(14): 3286-95.
199. Hueber, A.O. and G.I. Evan, Traps to catch unwary oncogenes. *Trends Genet*, 1998. 14(9): 364-7.
200. Amati, B., K. Alevizopoulos, and J. Vlach, Myc and the cell cycle. *Front Biosci*, 1998. 3: d250-68.
201. Ponzelli, R., et al., Cancer therapeutics: targeting the dark side of Myc. *Eur J Cancer*, 2005. 41(16): 2485-501.
202. Hecht, J.L. and J.C. Aster, Molecular biology of Burkitt's lymphoma. *J Clin Oncol*, 2000. 18(21): 3707-21.



203. Hogarty, M.D., The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification. *Cancer Lett*, 2003. 197(1-2): 173-9.
204. Sears, R., et al., Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. *Genes Dev*, 2000. 14(19): 2501-14.
205. Felsher, D.W. and J.M. Bishop, Transient excess of MYC activity can elicit genomic instability and tumorigenesis. *Proc Natl Acad Sci U S A*, 1999. 96(7): 3940-4.
206. Oster, S.K., et al., The myc oncogene: Marvelously Complex. *Adv Cancer Res*, 2002. 84: 81-154.
207. Soucek, L., et al., Modelling Myc inhibition as a cancer therapy. *Nature*, 2008. 455(7213): 679-83.
208. Hayday, A.C., et al., Activation of a translocated human c-myc gene by an enhancer in the immunoglobulin heavy-chain locus. *Nature*, 1984. 307(5949): 334-40.
209. Hunt, K.E. and K.K. Reichard, Diffuse large B-cell lymphoma. *Arch Pathol Lab Med*, 2008. 132(1): 118-24.
210. Fujisawa, S., et al., CD5+ diffuse large B-cell lymphoma with c-myc/IgH rearrangement presenting as primary effusion lymphoma. *Int J Hematol*, 2005. 81(4): 315-8.
211. Au, W.Y., et al., The spectrum of lymphoma with 8q24 aberrations: a clinical, pathological and cytogenetic study of 87 consecutive cases. *Leuk Lymphoma*, 2004. 45(3): 519-28.
212. Niitsu, N., et al., t(8;14)(q24;q32) in two patients with CD10-negative primary thyroid diffuse large B-cell lymphoma. *Leuk Res*, 2007. 31(5): 707-11.
213. Kluin, P.M., N.L. Harris, and H. Stein, B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, in *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*, S.H. Swerdlow, E. Campo, and N.L. Harris, Editors. 2008, IARC Press: Lyon, France. 265-266.
214. Nobuyoshi, M., et al., Increased expression of the c-myc gene may be related to the aggressive transformation of human myeloma cells. *Br J Haematol*, 1991. 77(4): 523-8.
215. Shou, Y., et al., Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. *Proc Natl Acad Sci U S A*, 2000. 97(1): 228-33.
216. Avet-Loiseau, H., et al., Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. *Blood*, 2001. 98(10): 3082-6.

217. Tarlinton, D., et al., Plasma cell differentiation and survival. *Curr Opin Immunol*, 2008. 20(2): 162-9.
218. Kunkel, E.J. and E.C. Butcher, Plasma-cell homing. *Nat Rev Immunol*, 2003. 3(10): 822-9.
219. Husband, A.J. and J.L. Gowans, The origin and antigen-dependent distribution of IgA-containing cells in the intestine. *J Exp Med*, 1978. 148(5): 1146-60.
220. Gualco, G., L.M. Weiss, and C.E. Bacchi, MUM1/IRF4: A Review. *Appl Immunohistochem Mol Morphol*, 2010. 18(4): 301-10.
221. Sze, D.M., et al., Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival. *J Exp Med*, 2000. 192(6): 813-21.
222. Baumgarth, N., A two-phase model of B-cell activation. *Immunol Rev*, 2000. 176: 171-80.
223. Alexander, D.D., et al., Multiple myeloma: a review of the epidemiologic literature. *Int J Cancer*, 2007. 120 Suppl 12: 40-61.
224. Stewart, A.K., et al., A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. *Leukemia*, 2007. 21(3): 529-34.
225. Bergsagel, P.L., et al., Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. *Proc Natl Acad Sci U S A*, 1996. 93(24): 13931-6.
226. Debes-Marun, C.S., et al., Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. *Leukemia*, 2003. 17(2): 427-36.
227. Bergsagel, P.L. and W.M. Kuehl, Chromosome translocations in multiple myeloma. *Oncogene*, 2001. 20(40): 5611-22.
228. Liebisch, P. and H. Dohner, Cytogenetics and molecular cytogenetics in multiple myeloma. *Eur J Cancer*, 2006. 42(11): 1520-9.
229. Tonon, G., Molecular pathogenesis of multiple myeloma. *Hematol Oncol Clin North Am*, 2007. 21(6): 985-1006, vii.
230. Fonseca, R., et al., Genetics and cytogenetics of multiple myeloma: a workshop report. *Cancer Res*, 2004. 64(4): 1546-58.
231. Bergsagel, P.L., et al., Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. *Blood*, 2005. 106(1): 296-303.
232. Chang, H., et al., p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. *Blood*, 2005. 105(1): 358-60.

233. Kuehl, W.M., et al., Dysregulation of c-myc in multiple myeloma. *Curr Top Microbiol Immunol*, 1997. 224: 277-82.
234. Dib, A., et al., Characterization of MYC translocations in multiple myeloma cell lines. *J Natl Cancer Inst Monogr*, 2008(39): 25-31.
235. Stewart, A.K. and R. Fonseca, Review of molecular diagnostics in multiple myeloma. *Expert Rev Mol Diagn*, 2007. 7(4): 453-9.
236. Bachar, G., et al., Solitary extramedullary plasmacytoma of the head and neck--long-term outcome analysis of 68 cases. *Head Neck*, 2008. 30(8): 1012-9.
237. Susnerwala, S.S., et al., Extramedullary plasmacytoma of the head and neck region: clinicopathological correlation in 25 cases. *Br J Cancer*, 1997. 75(6): 921-7.
238. Grogan, T.M., et al., Plasma cell neoplasms, in *Pathology & Genetics. Tumours of haematopoietic and lymphoid tissues*, E.S. Jaffe, H. Stein, and J.W. Vardiman, Editors. 2001, IARC Publisher: Lyon, France. 142-156.
239. Avet-Loiseau, H., et al., Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. *Blood*, 2001. 97(3): 822-5.
240. Chang, H., et al., Genomic aberrations in plasma cell leukemia shown by interphase fluorescence in situ hybridization. *Cancer Genet Cytogenet*, 2005. 156(2): 150-3.
241. Cook, J.R., Paraffin section interphase fluorescence in situ hybridization in the diagnosis and classification of non-hodgkin lymphomas. *Diagn Mol Pathol*, 2004. 13(4): 197-206.
242. Tibiletti, M.G., et al., The applications of FISH in tumor pathology. *Adv Clin Path*, 1999. 3(4): 111-8.
243. Tanas, M.R. and J.R. Goldblum, Fluorescence in situ hybridization in the diagnosis of soft tissue neoplasms: a review. *Adv Anat Pathol*, 2009. 16(6): 383-91.
244. Tibiletti, M.G., Interphase FISH as a new tool in tumor pathology. *Cytogenet Genome Res*, 2007. 118(2-4): 229-36.
245. Haralambieva, E., et al., Detection of three common translocation breakpoints in non-Hodgkin's lymphomas by fluorescence in situ hybridization on routine paraffin-embedded tissue sections. *J Pathol*, 2002. 198(2): 163-70.
246. Raviele, P., G. Pruneri, and E. Maiorano, Plasmablastic lymphoma: a review. *Oral Dis*, 2008. 15(1): 38-45.

247. UNAIDS, Report on the global AIDS epidemic. 2008, WHO Library Cataloguing-in-Publication Data: Geneva, Switzerland. 33.
248. Classification and diagnostic criteria for oral lesions in HIV infection. EC-Clearinghouse on Oral Problems Related to HIV Infection and WHO Collaborating Centre on Oral Manifestations of the Immunodeficiency Virus. *J Oral Pathol Med*, 1993. 22(7): 289-91.
249. Ely, S.A. and D.M. Knowles, Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. *Am J Pathol*, 2002. 160(4): 1293-9.
250. Cheang, M.C., et al., Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. *J Clin Oncol*, 2006. 24(36): 5637-44.
251. Cheuk, W., et al., Consistent immunostaining for cyclin D1 can be achieved on a routine basis using a newly available rabbit monoclonal antibody. *Am J Surg Pathol*, 2004. 28(6): 801-7.
252. Groves, D.J. and B.A. Morris, Veterinary sources of nonrodent monoclonal antibodies: interspecific and intraspecific hybridomas. *Hybridoma*, 2000. 19(3): 201-14.
253. Seegmiller, A.C., et al., Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma. *Am J Clin Pathol*, 2007. 127(2): 176-81.
254. Dahl, I.M., et al., Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. *Br J Haematol*, 2002. 116(2): 273-7.
255. Chu, P.G. and D.A. Arber, CD79: a review. *Appl Immunohistochem Mol Morphol*, 2001. 9(2): 97-106.
256. Tanaka, T., et al., Frequent downregulation or loss of CD79a expression in plasma cell myelomas: potential clue for diagnosis. *Pathol Int*, 2009. 59(11): 804-8.
257. Tseng, J., B.J. Eisfelder, and M.R. Clark, B-cell antigen receptor-induced apoptosis requires both Ig alpha and Ig beta. *Blood*, 1997. 89(5): 1513-20.
258. Pike, K.A., et al., The cytoplasmic domain of Ig alpha is necessary and sufficient to support efficient early B cell development. *J Immunol*, 2004. 172(4): 2210-8.

259. Falini, B., et al., A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. *Blood*, 2000. 95(6): 2084-92.
260. Mittrucker, H.W., et al., Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. *Science*, 1997. 275(5299): 540-3.
261. Natkunam, Y., et al., Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. *Mod Pathol*, 2001. 14(7): 686-94.
262. Xu, D., et al., Interferon regulatory factor 4 is involved in Epstein-Barr virus-mediated transformation of human B lymphocytes. *J Virol*, 2008. 82(13): 6251-8.
263. Caraux, A., et al., Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells. *Haematologica*, 2010. 95(6): 1016-20.
264. Carbone, A., et al., Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. *Blood*, 1998. 91(3): 747-55.
265. Malavasi, F., et al., Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. *Physiol Rev*, 2008. 88(3): 841-86.
266. Lima, M., et al., Immunophenotypic aberrations, DNA content, and cell cycle analysis of plasma cells in patients with myeloma and monoclonal gammopathies. *Blood Cells Mol Dis*, 2000. 26(6): 634-45.
267. Thomas, M.L. and L. Lefrancois, Differential expression of the leucocyte-common antigen family. *Immunol Today*, 1988. 9(10): 320-6.
268. Trowbridge, I.S. and M.L. Thomas, CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. *Annu Rev Immunol*, 1994. 12: 85-116.
269. Kumar, S., et al., CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. *Leukemia*, 2005. 19(8): 1466-70.
270. Rafaniello Raviele, P., G. Pruneri, and E. Maiorano, Plasmablastic lymphoma: a review. *Oral Dis*, 2009. 15(1): 38-45.
271. Onciu, M., et al., ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. *Blood*, 2003. 102(7): 2642-4.
272. Reichard, K.K., R.W. McKenna, and S.H. Kroft, Comparative analysis of light chain expression in germinal center cells and mantle cells of reactive

- lymphoid tissues. A four-color flow cytometric study. *Am J Clin Pathol*, 2003. 119(1): 130-6.
273. Bayer-Garner, I.B., V.G. Prieto, and B.R. Smoller, Detection of clonality with kappa and lambda immunohistochemical analysis in cutaneous plasmacytomas. *Arch Pathol Lab Med*, 2004. 128(6): 645-8.
274. Boo, K. and S. Cheng, A morphological and immunohistochemical study of plasma cell proliferative lesions. *Malays J Pathol*, 1992. 14(1): 45-8.
275. Coriu, D., et al., A molecular basis for nonsecretory myeloma. *Blood*, 2004. 104(3): 829-31.
276. Minhas, V., et al., Early childhood infection by human herpesvirus 8 in Zambia and the role of human immunodeficiency virus type 1 coinfection in a highly endemic area. *Am J Epidemiol*, 2008. 168(3): 311-20.
277. Gomez-Roman, J.J., et al., Presence of human herpesvirus 8 DNA sequences in renal transplantation-associated pleural Kaposi sarcoma. *Arch Pathol Lab Med*, 1999. 123(12): 1269-73.
278. Dedicoat, M. and R. Newton, Review of the distribution of Kaposi's sarcoma-associated herpesvirus (KSHV) in Africa in relation to the incidence of Kaposi's sarcoma. *Br J Cancer*, 2003. 88(1): 1-3.
279. Chagas, C.A., et al., Detection of herpesvirus type 8 (HHV8) in children's tonsils and adenoids by immunohistochemistry and in situ hybridization. *Int J Pediatr Otorhinolaryngol*, 2006. 70(1): 65-72.
280. Allday, M.J., How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma? *Semin Cancer Biol*, 2009. 19(6): 366-76.
281. Young, L.S. and A.B. Rickinson, Epstein-Barr virus: 40 years on. *Nat Rev Cancer*, 2004. 4(10): 757-68.
282. Wong, H.H. and J. Wang, Epstein-Barr virus positive diffuse large B-cell lymphoma of the elderly. *Leuk Lymphoma*, 2009. 50(3): 335-40.
283. Piriou, E., et al., Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma. *Blood*, 2005. 106(9): 3166-74.
284. Kamranvar, S.A., et al., Epstein-Barr virus promotes genomic instability in Burkitt's lymphoma. *Oncogene*, 2007. 26(35): 5115-23.
285. Drotar, M.E., et al., Epstein-Barr virus nuclear antigen-1 and Myc cooperate in lymphomagenesis. *Int J Cancer*, 2003. 106(3): 388-95.
286. van den Bosch, C.A., Is endemic Burkitt's lymphoma an alliance between three infections and a tumour promoter? *Lancet Oncol*, 2004. 5(12): 738-46.



287. Roughan, J.E. and D.A. Thorley-Lawson, The intersection of Epstein-Barr virus with the germinal center. *J Virol*, 2009. 83(8): 3968-76.
288. Schurter, M.J., D.P. LeBrun, and K.J. Harrison, Improved technique for fluorescence in situ hybridisation analysis of isolated nuclei from archival, B5 or formalin fixed, paraffin wax embedded tissue. *Mol Pathol*, 2002. 55(2): 121-4.
289. Bernicot, I., et al., Molecular cytogenetics of IGH rearrangements in non-Hodgkin B-cell lymphoma. *Cytogenet Genome Res*, 2007. 118(2-4): 345-52.
290. Gabrea, A., et al., Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors. *Genes Chromosomes Cancer*, 2008. 47(7): 573-90.
291. Boerma, E.G., et al., Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of today's knowledge. *Leukemia*, 2009. 23(2): 225-34.
292. Barrans, S., et al., Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. *J Clin Oncol*, 2010. 28(20): 3360-5.
293. Smith, S.M., et al., The impact of MYC expression in lymphoma biology: Beyond Burkitt lymphoma. *Blood Cells Mol Dis*, 2010. 45(4): 317-23.
294. Eilers, M. and R.N. Eisenman, Myc's broad reach. *Genes Dev*, 2008. 22(20): 2755-66.
295. Dang, C.V., Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. *Cancer Res*, 2010. 70(3): 859-62.
296. Brandvold, K.A., P. Neiman, and A. Ruddell, Angiogenesis is an early event in the generation of myc-induced lymphomas. *Oncogene*, 2000. 19(23): 2780-5.
297. Zhang, J., et al., Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. *Cancer Res*, 2009. 69(12): 5082-90.
298. Klapproth, K. and T. Wirth, Advances in the understanding of MYC-induced lymphomagenesis. *Br J Haematol*, 2010. 149(4): 484-97.
299. Al Tabaa, Y., et al., Functional Epstein-Barr virus reservoir in plasma cells derived from infected peripheral blood memory B cells. *Blood*, 2009. 113(3): 604-11.
300. Pegtel, D.M., J. Middeldorp, and D.A. Thorley-Lawson, Epstein-Barr virus infection in ex vivo tonsil epithelial cell cultures of asymptomatic carriers. *J Virol*, 2004. 78(22): 12613-24.

301. Wessendorf, S., et al., Hidden gene amplifications in aggressive B-cell non-Hodgkin lymphomas detected by microarray-based comparative genomic hybridization. *Oncogene*, 2003. 22(9): 1425-9.
302. Tinguely, M., et al., Chromosomal translocations t(4;14), t(11;14) and proliferation rate stratify patients with mature plasma cell myelomas into groups with different survival probabilities: a molecular epidemiologic study on tissue microarrays. *Am J Surg Pathol*, 2007. 31(5): 690-6.
303. Specht, K., et al., Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. *Blood*, 2004. 104(4): 1120-6.
304. Wang, S.S., et al., Cyclin D1 splice variant and risk for non-Hodgkin lymphoma. *Hum Genet*, 2006. 120(2): 297-300.
305. Christie, L., et al., C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: An adverse prognostic indicator? *Leuk Lymphoma*, 2008. 49(3): 470-6.
306. Mead, G.M., et al., A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). *Blood*, 2008. 112(6): 2248-60.
307. May, P.C., et al., Detection of cryptic and variant IGH-MYC rearrangements in high-grade non-Hodgkin's lymphoma by fluorescence in situ hybridization: implications for cytogenetic testing. *Cancer Genet Cytogenet*, 2010. 198(1): 71-5.
308. Einerson, R.R., et al., Novel FISH probes designed to detect IGK-MYC and IGL-MYC rearrangements in B-cell lineage malignancy identify a new breakpoint cluster region designated BVR2. *Leukemia*, 2006. 20(10): 1790-9.
309. Joos, S., et al., Variable breakpoints in Burkitt lymphoma cells with chromosomal t(8;14) translocation separate c-myc and the IgH locus up to several hundred kb. *Hum Mol Genet*, 1992. 1(8): 625-32.
310. Johnson, N.A., et al., Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. *Blood*, 2009. 114(11): 2273-9.
311. Ruzinova, M.B., T. Caron, and S.J. Rodig, Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation. *Am J Surg Pathol*, 2010. 34(6): 882-91.
312. Lo Coco, F., et al., Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. *Blood*, 1994. 83(7): 1757-9.

313. Offit, K., et al., Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. *N Engl J Med*, 1994. 331(2): 74-80.
314. Sawyer, J.R., et al., Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. *Br J Haematol*, 2001. 112(1): 167-74.
315. Bink, K., et al., Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics. *Haematologica*, 2008. 93(4): 623-6.
316. Li, J.Y., et al., Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization. *Am J Pathol*, 1999. 154(5): 1449-52.
317. Tan, L.H., et al., Detection of ALK gene rearrangements in formalin-fixed, paraffin-embedded tissue using a fluorescence in situ hybridization (FISH) probe: a search for optimum conditions of tissue archiving and preparation for FISH. *Mol Diagn*, 2003. 7(1): 27-33.
318. Tubbs, R.R., et al., Molecular pathology testing of tissues fixed in prefer solution. *Am J Surg Pathol*, 2004. 28(3): 417-9.